Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M10,206Revenue $M548Net Margin (%)-32.2Z-Score6.7
Enterprise Value $M10,020EPS $-1.3Operating Margin %-28.4F-Score4
P/E(ttm))0Cash Flow Per Share $-0.1Pre-tax Margin (%)-32.2Higher ROA y-yN
Price/Book6.510-y EBITDA Growth Rate %0Quick Ratio6.2Cash flow > EarningsY
Price/Sales16.05-y EBITDA Growth Rate %0Current Ratio7.3Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-7.8Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-13.2Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M146ROI % (ttm)-9.2Gross Margin Increase y-yY

Gurus Latest Trades with BMRN

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BMRNFrank Sands 2014-06-30 Add0.35%$56.15 - $68.61
($60.38)
$ 69.3715%Add 22.47%11,925,248
BMRNRay Dalio 2014-06-30 Sold Out -0.03%$56.15 - $68.61
($60.38)
$ 69.3715%Sold Out0
BMRNJohn Burbank 2014-06-30 Sold Out -0.01%$56.15 - $68.61
($60.38)
$ 69.3715%Sold Out0
BMRNRay Dalio 2014-03-31 Buy 0.03%$64.99 - $83.28
($73.66)
$ 69.37-6%New holding, 48400 sh.48,400
BMRNJohn Burbank 2014-03-31 Buy 0.01%$64.99 - $83.28
($73.66)
$ 69.37-6%New holding, 5173 sh.5,173
BMRNJohn Griffin 2013-12-31 Add0.23%$59.3 - $75.09
($67.74)
$ 69.372%Add 17.71%2,060,000
BMRNFrank Sands 2013-09-30 Reduce-0.2%$58.64 - $78.388
($66.48)
$ 69.374%Reduce -9.49%10,268,812
BMRNMeridian Funds 2013-06-30 Sold Out -0.09%$54.72 - $70.3
($62.32)
$ 69.3711%Sold Out0
BMRNFrank Sands 2013-03-31 Add0.24%$49.2 - $62.39
($56.51)
$ 69.3723%Add 10.9%10,951,298
BMRNMeridian Funds 2013-03-31 Reduce-0.17%$49.2 - $62.39
($56.51)
$ 69.3723%Reduce -69.03%40,700
BMRNFrank Sands 2012-12-31 Add1.56%$36.78 - $50.17
($45.59)
$ 69.3752%Add 450.74%9,874,728
BMRNDaniel Loeb 2012-12-31 Sold Out -0.79%$36.78 - $50.17
($45.59)
$ 69.3752%Sold Out0
BMRNMeridian Funds 2012-12-31 Reduce-0.3%$36.78 - $50.17
($45.59)
$ 69.3752%Reduce -60.99%131,400
BMRNJohn Griffin 2012-12-31 Reduce-0.28%$36.78 - $50.17
($45.59)
$ 69.3752%Reduce -20.09%1,750,000
BMRNJohn Griffin 2012-09-30 Buy 1.4%$37.23 - $43.29
($39.41)
$ 69.3776%New holding, 2190000 sh.2,190,000
BMRNDaniel Loeb 2012-09-30 Buy 0.79%$37.23 - $43.29
($39.41)
$ 69.3776%New holding, 1000000 sh.1,000,000
BMRNGeorge Soros 2012-06-30 Sold Out -0.15%$32.53 - $38.87
($36.01)
$ 69.3793%Sold Out0
BMRNRichard Perry 2012-06-30 Sold Out -0.04%$32.53 - $38.87
($36.01)
$ 69.3793%Sold Out0
BMRNGeorge Soros 2012-03-31 Add0.11%$33.68 - $38.34
($32.99)
$ 69.37110%Add 300%300,000
BMRNRichard Perry 2012-03-31 Buy 0.04%$33.68 - $38.34
($32.99)
$ 69.37110%New holding, 22900 sh.22,900
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BMRN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
BMRN Frank Sands 2014-06-3011,925,2488.171.9+22.47%
BMRN John Griffin 2014-06-302,100,0001.441.3+1.94%
BMRN PRIMECAP Management 2014-06-308,064,2195.530.55-1.22%
BMRN Ray Dalio 2014-06-30000Sold Out
BMRN John Burbank 2014-06-30000Sold Out
BMRN Meridian Funds 2013-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


BMRN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
FUCHS HENRY JEVP, Chief Medical Officer 2014-08-05Sell10,000$656.72view
SPIEGELMAN DANIEL KEVP, CFO 2014-08-01Sell2,229$61.7612.32view
SPIEGELMAN DANIEL KEVP, CFO 2014-07-02Sell2,229$648.39view
BIENAIME JEAN JACQUESCEO 2014-06-04Sell2,000$61.213.35view
Ajer Jeffrey RobertSVP, Chief Commercial Of 2014-06-02Sell377$57.8319.96view
BIENAIME JEAN JACQUESCEO 2014-05-22Sell1,000$56.8821.96view
BIENAIME JEAN JACQUESCEO 2014-05-21Sell1,545$56.1923.46view
Ajer Jeffrey RobertSVP, Chief Commercial Of 2014-05-16Sell1,004$56.9121.89view
FUCHS HENRY JEVP, Chief Medical Officer 2014-05-16Sell1,864$56.8622view
LAWLIS V BRYANDirector 2014-05-16Sell1,700$56.8721.98view

Press Releases about BMRN :

    Quarterly/Annual Reports about BMRN:

    News about BMRN:

    Articles On GuruFocus.com
    You Can No Longer Ignore Biotech Feb 07 2014 
    Weekly Top Insider Sells: AAPL, GILD, BMRN, and PCLN Nov 19 2012 
    WEEKLY CFO SELLS HIGHLIGHT: VVUS, DIS, SNPS, TXRH, BMRN Mar 04 2012 
    5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
    Weekly CFO Sells Highlight: MSCC, BMRN, VAL, CUTR, REX, CIEN Oct 02 2011 
    BioMarin Pharmaceutical Inc. Reports Operating Results (10-K) Feb 24 2011 
    BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 1,000 Shares Dec 13 2010 
    BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 2,000 Shares Dec 13 2010 
    BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 1,000 Shares Dec 07 2010 
    BioMarin Pharmaceutical Inc. (BMRN) SVP, CFO Jeffrey H Cooper sells 11,250 Shares Nov 24 2010 

    More From Other Websites
    BioMarin to Present at Upcoming Investor Conferences Aug 19 2014
    BioMarin to Present at Upcoming Investor Conferences Aug 19 2014
    BIOMARIN PHARMACEUTICAL INC Financials Aug 08 2014
    Scott Drake, CEO, and Guy A. Childs, CFO of The Spectranetics Corporation (SPNC), Interview with The... Aug 08 2014
    NPS Pharma Reports Earnings in Q2 on Strong Gattex Sales Aug 07 2014
    BioMarin Weathers The Storm Aug 06 2014
    4 Top Drugmakers Deliver Solid Doses Of Earnings Growth Aug 05 2014
    BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement Aug 01 2014
    BioMarin Q2 Loss Narrower than Expected, Revenue Guidance Up Jul 31 2014
    BIOMARIN PHARMACEUTICAL INC Files SEC form 10-Q, Quarterly Report Jul 31 2014
    BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 30 2014
    BioMarin Announces Second Quarter 2014 Financial Results Jul 30 2014
    BioMarin Sells Priority Review Voucher for $67.5 Million Jul 30 2014
    Biotech Stock Roundup: Gilead's Sovaldi & Biogen's Tecfidera Impressive Run Continues Jul 30 2014
    Q2 2014 BioMarin Pharmaceutical Inc. Earnings Release - After Market Close Jul 30 2014
    [video] What's coming in biotech? Jul 23 2014
    Cubist Misses Q2 Earnings Estimates on Weak Cubicin Sales Jul 23 2014
    Sarah Cannon Research UK and BioMarin Collaborate on EMBRACA Clinical Study in Hereditary Breast... Jul 23 2014
    Sarah Cannon Research UK and BioMarin Collaborate on EMBRACA Clinical Study in Hereditary Breast... Jul 23 2014
    Arena Pharmaceuticals' Pain Candidate Gets New U.S. Patent Jul 16 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide